Department of Medical Oncology, Oncopole Claudius Regaud, IUCT-O, Toulouse, France

F. Poumeaud & F. Dalenc

Biostatistics & Health Data Science Unit, Oncopole Claudius Regaud IUCT-O, Toulouse, France

M. Morisseau & B. Cabarrou

Department of Medical Oncology, Institut Curie, Paris, France

L. Cabel & D. Loirat

Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France

A. Gonçalves & A. de Nonneville

Department of Medical Oncology, Centre Léon Bérard, Cancer Research Center of Lyon (UMR Inserm 1052 – CNRS 5286), Lyon, France

C. Rivier & O. Trédan

Department of Medical Oncology, Institut de cancérologie de l’Ouest, Saint-Herblain, France

E. Volant & J.-S. Frenel

Department of Medical Oncology, Centre Georges-François Leclerc, INSERM U1231, Dijon, France

S. Ladoire

Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, INSERM U1194, Montpellier, France

W. Jacot

Department of Medical Oncology and Cellular Therapy, Faculté de médecine Sorbonne Université, Hôpital Tenon, Paris, France

M. Jamelot

Department of Medical Oncology, Hôpital de la Pitié-Salpêtrière, Institut Universitaire de Cancérologie AP-HP, Sorbonne Université, Paris, France

H. Foka Tichoue

Department of Medical Oncology, Institut de Cancérologie de l’Ouest Pays de la Loire, Angers, France

A. Patsouris

Department of Medical Oncology, INSERM U976, Université de Paris Cité, Hopital Saint Louis, Paris, France

L. Teixeira

Department of Medical Oncology, Institut Curie, Saint-Cloud, France

F.-C. Bidard

Versailles Saint-Quentin University, Paris Saclay, Saint-Cloud, France

F.-C. Bidard

Clinical Trials Department – Breast Cancers, Institut Bergonié, Bordeaux, France

M. Brunet

Department of Medical Oncology, Centre François Baclesse, Caen, France

C. Levy

Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France

C. Bailleux

Department of Medical Oncology, Centre Eugène Marquis, Rennes, France

A. Deleuze

Department of Medical Oncology, Institut de Cancérologie de Lorraine, Nancy, France

L. Uwer

Department of Medical Oncology, Centre Hospitalier Universitaire de Limoges, Limoges, France

E. Deluche

Department of Medical Oncology, Centre Hospitalier de la côte basque, Bayonne, France

T. Grellety

Department of Pathology, Oncopole Claudius Regaud, IUCT-O, Toulouse, France

C. Franchet

Department of Medical Oncology, University Hospital, Nimes, France

F. Fiteni

UMR INSERM IDESP—Desbrest Institute of Epidemiology and Public Health, University of Montpellier, Montpellier, France

F. Fiteni

Department of Medical Oncology, Institut de Cancérologie de Strasbourg Europe, Strasbourg, France

H. Bischoff

Department of Medical Oncology, Centre Henri Becquerel, Rouen, France

R. Vion

University Paris-Saclay, Gustave Roussy, INSERM U981, Molecular Predictors and New Targets in Oncology, Villejuif, France

M. Pagliuca

Division of Breast Medical Oncology, Instituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italia

M. Pagliuca

Departmentof Medical Oncology, Institut Gustave Roussy, Paris, France

B. Verret

Department of Medical Oncology, Centre Oscar Lambret, Lille, France

S. Bécourt

Department of Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Université Lyon 1, Lyon, France

T. Reverdy

FP and FD: conceived and designed the study that led to the submission, acquired data, drafted and revised the manuscript, approved the final version and agreed to be accountable for all aspects of the study. MM: played an important role in interpreting the results, drafted and revised the manuscript, approved the final version and agreed to be accountable for all aspects of the study. BC: played an important role in interpreting the results, revised the manuscript, approved the final version and agreed to be accountable for all aspects of the study. JSF, WJ and AdN: played an important role in interpreting the results, acquired data, revised the manuscript, approved the final version and agreed to be accountable for all aspects of the study. LC, AG, CR, OT, EV, SL, MJ, HF, AP, LT, F-CB, DL, MB, CL, CB, AD, LU, ED, TG, CF, FF, HB, RV, MP, BV, SB and TR: acquired data, revised the manuscript, approved the final version and agreed to be accountable for all aspects of the study.